BACKGROUND: Few studies have investigated the impact of chronic hepatitis B and C infection on antiretroviral therapy (ART) outcomes in sub-Saharan Africa. Hepatotoxicity may be a particular concern in co-infected patients taking nevirapine-stavudine-lamivudine. METHODS: We conducted a prospective cohort study of 300 Malawian adults starting ART and describe one-year ART outcomes according to viral hepatitis status. RESULTS: At baseline, patients had advanced HIV disease (29.3% were in WHO stage 4; mean CD4 = 157 cells/microL; mean log(10)HIV-1 RNA = 5.24 copies/ml). Co-infection with hepatitis B, C and B + C were present in 6.7%, 5.7% and 1.7% respectively. At 50 weeks, all-cause mortality was 43 (14.3%). Sixteen (5.3%) had transferred to another unit. Eight (2.7%) were lost to follow up. Sixteen (5.3%) had stopped ART. 217 (72.3%) were alive on ART, of whom 82.5% had an HIV-1 RNA <400 copies/ml at week 50. During the first 50 weeks of ART, severe hepatotoxicity (liver enzyme values >5 times upper level of normal) occurred in 9%, but did not result in any ART discontinuations. Clinical hepatitis or jaundice was not observed. There were no significant differences in occurrence of hepatotoxicity, other side effects, mortality, severe morbidity, immune reconstitution or virological failure between hepatitis B and/or C co-infected patients and those who were not. Viral hepatitis co-infection was not associated with severe hepatotoxicity, mortality, severe morbidity or virological failure in multivariate analyses. CONCLUSION: Our data suggest that screening for viral hepatitis B and C and liver enzyme monitoring may not require high priority in ART programmes in sub-Saharan Africa.
BACKGROUND: Few studies have investigated the impact of chronic hepatitis B and C infection on antiretroviral therapy (ART) outcomes in sub-Saharan Africa. Hepatotoxicity may be a particular concern in co-infected patients taking nevirapine-stavudine-lamivudine. METHODS: We conducted a prospective cohort study of 300 Malawian adults starting ART and describe one-year ART outcomes according to viral hepatitis status. RESULTS: At baseline, patients had advanced HIV disease (29.3% were in WHO stage 4; mean CD4 = 157 cells/microL; mean log(10)HIV-1 RNA = 5.24 copies/ml). Co-infection with hepatitis B, C and B + C were present in 6.7%, 5.7% and 1.7% respectively. At 50 weeks, all-cause mortality was 43 (14.3%). Sixteen (5.3%) had transferred to another unit. Eight (2.7%) were lost to follow up. Sixteen (5.3%) had stopped ART. 217 (72.3%) were alive on ART, of whom 82.5% had an HIV-1 RNA <400 copies/ml at week 50. During the first 50 weeks of ART, severe hepatotoxicity (liver enzyme values >5 times upper level of normal) occurred in 9%, but did not result in any ART discontinuations. Clinical hepatitis or jaundice was not observed. There were no significant differences in occurrence of hepatotoxicity, other side effects, mortality, severe morbidity, immune reconstitution or virological failure between hepatitis B and/or C co-infected patients and those who were not. Viral hepatitis co-infection was not associated with severe hepatotoxicity, mortality, severe morbidity or virological failure in multivariate analyses. CONCLUSION: Our data suggest that screening for viral hepatitis B and C and liver enzyme monitoring may not require high priority in ART programmes in sub-Saharan Africa.
Authors: James H McMahon; Julian H Elliott; Silvia Bertagnolio; Rachel Kubiak; Michael R Jordan Journal: Bull World Health Organ Date: 2013-02-21 Impact factor: 9.408
Authors: Charles S Chasela; Patrick Wall; Jan Drobeniuc; Caroline C King; Eyasu Teshale; Mina C Hosseinipour; Sascha R Ellington; Mary Codd; Denise J Jamieson; Rodney J Knight; Patricia Fitzpatrick; Athena P Kourtis; Irving F Hoffman; Dumbani Kayira; Noel Mumba; Deborah D Kamwendo; Francis Martinson; William Powderly; Charles van der Horst; Saleem Kamili Journal: J Clin Virol Date: 2012-06-02 Impact factor: 3.168
Authors: Samir Aoudjane; Mas Chaponda; Antonio Adrián González Del Castillo; Jemma O'Connor; Marc Noguera; Apostolos Beloukas; Mark Hopkins; Saye Khoo; Joep J van Oosterhout; Anna Maria Geretti Journal: Clin Infect Dis Date: 2014-08-06 Impact factor: 9.079
Authors: Helen M Chun; Octavio Mesner; Chloe L Thio; Ionut Bebu; Grace Macalino; Brian K Agan; William P Bradley; Jennifer Malia; Sheila A Peel; Linda L Jagodzinski; Amy C Weintrob; Anuradha Ganesan; Mary Bavaro; Jason D Maguire; Michael L Landrum Journal: J Acquir Immune Defic Syndr Date: 2014-06-01 Impact factor: 3.731
Authors: James H McMahon; Julian H Elliott; Steven Y Hong; Silvia Bertagnolio; Michael R Jordan Journal: PLoS One Date: 2013-02-12 Impact factor: 3.240
Authors: Kenneth C Kapembwa; Jason D Goldman; Shabir Lakhi; Yolan Banda; Kasonde Bowa; Sten H Vermund; Joseph Mulenga; David Chama; Benjamin H Chi Journal: J Glob Infect Dis Date: 2011-07
Authors: Duncan Ndegwa Maina; Andrew Kimanga Nyerere; Ruth Wambui Gicho; Joseph Maina Mwangi; Raphael Wekesa Lihana Journal: East Afr Health Res J Date: 2017-07-01